Who is sponsoring NCT03993639?

NCT03993639 is sponsored by Kyowa Kirin Co., Ltd..

What drugs are being tested in NCT03993639?

Interventions in NCT03993639: Pegfilgrastim.

What condition does NCT03993639 study?

NCT03993639 studies Peripheral Blood Stem Cell Transplantation.

Is NCT03993639 still recruiting?

NCT03993639 is currently completed. Last updated 22 January 2021.

Last reviewed 2021-01-22 · How we verify

NCT03993639

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KRN125 for Mobilization of Hematopoietic Stem Cells

Completed Phase 2 Last updated 22 January 2021

What this trial tests

Phase 2 trial testing Pegfilgrastim in Peripheral Blood Stem Cell Transplantation in 35 participants. Completed in 28 August 2020.

Timeline

28 May 2019

Primary endpoint
21 July 2020

28 August 2020

Quick facts

Lead sponsor	Kyowa Kirin Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	28 May 2019
Primary completion	21 July 2020
Estimated completion	28 August 2020
Sites	1 location across Japan

Drugs / interventions tested

Pegfilgrastim (PEGFILGRASTIM) — full drug profile →

Conditions studied

Peripheral Blood Stem Cell Transplantation — all drugs for Peripheral Blood Stem Cell Transplantation →

Sponsor

Kyowa Kirin Co., Ltd. — full company profile →

Who can join

Adults 20 to 55, any sex, with Peripheral Blood Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Data collection to evaluate safety and effect of hematopoietic stem cell mobilization into the peripheral blood after a single subcutaneous (SC) dose of KRN125(Pegfilgrastim)in healthy adults.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and Safety of Single-dose Pegfilgrastim for CD34 + Cell Mobilization in Healthy Volunteers: A Phase 2 Study.
Goto H, Sugita J, Hasegawa Y, Hayasaka K, et al · · 2024 · cited 2× · PMID 38012835 · DOI 10.1097/tp.0000000000004880

Verify or expand the search:

Other trials of Pegfilgrastim

Trials testing the same drug.

NCT07021989 — ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma · Phase 2 · not yet recruiting
NCT06738368 — Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin · Phase 2 · recruiting
NCT07278856 — Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphoma · Phase 1 · not yet recruiting
NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07224100 — Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosom · Phase 2 · recruiting

Other recruiting trials for Peripheral Blood Stem Cell Transplantation

Currently open trials in the same condition.

NCT05961410 — Eltrombopag for Peripheral Blood Stem Cell Harvest · Phase 2 · recruiting
NCT05436418 — The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofet · Phase 1, PHASE2 · recruiting

Other Kyowa Kirin Co., Ltd. trials

Trials by the same sponsor.

NCT06926491 — Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study） · Phase 3 · recruiting
NCT06812104 — Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia · Phase 1 · recruiting
NCT06525636 — A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia · Phase 1, PHASE2 · recruiting
NCT06116890 — Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration · Phase 2 · active not recruiting
NCT06116916 — Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03993639 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kyowa Kirin Co., Ltd.
Last refreshed: 22 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03993639.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing